Vivos Therapeutics宣布已与Streeterville资本签订一项具有法律约束力的协议，将进行一项最高金额达450万美元的优先债务转股权交易。此项融资安排旨在为公司提供必要资金支持，以确保其能够继续满足纳斯达克证券交易所的上市维持要求。
该债务转股权交易涉及将公司现有优先债务转换为股权资本，具体转换规模最高可达450万美元。通过这一结构性融资方案，Vivos Therapeutics不仅能够优化其资产负债表结构，降低债务负担，同时还能增强股东权益基础。Streeterville资本作为专业投资机构，此次参与体现了其对Vivos Therapeutics长期发展前景的信心。
完成此次交易后，公司预计将显著改善其资本状况，为持续运营和业务拓展提供更为稳固的财务基础。维持纳斯达克上市地位对于公司保持公开市场融资渠道、提升投资者信心以及扩大市场影响力具有重要战略意义。这一融资安排将支持公司继续推进其治疗解决方案的研发与商业化进程。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.